T76675
Clazakizumab
TargetMol
DESCRIPTION
Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under research for treating psoriatic arthritis (PsA) and renal antibody-mediated rejection [1] [2].
DETAILS
- Cas: 1236278-28-6
- Purity: 98%
- Category: Compound
Lead Time: 4 - 5 weeks
Sign in to view pricingEquivalent Items
| ... Loading